BioSpace News Archive

Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020 . Second Quarter FY2021 Snapshot Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million .

Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

IDEXX Achieves fourth quarter reported revenue growth of 19% and organic growth of 17%, driven by CAG Diagnostics recurring revenue reported growth of 23% and organic growth of 21% High revenue growth supported by sustained strong global trends in pet healthcare

- BX002 demonstrated safety and tolerability with successful delivery of a high concentration of viable phage to the lower gastrointestinal tract - - First clinical study detailing pharmacokinetics of oral phage therapy under a U.S. FDA IND protocol - - Efficacy results in reduction of target bacteria expected by mid-2022 from planned Phase 1b/2a study -

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA

Revitope Oncology, Inc., a biotechnology company advancing a new class of precision cancer immunotherapies, today announced the appointment of biotechnology pioneer Louis Lange , M.D., Ph.D., to its Board of Directors.

Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, announced today that the first healthy volunteer has been successfully dosed in a first-in-human Phase 1 clinical trial for its lead investigational therapy P014.

Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced it has entered into an exclusive license agreement with Ono Pharmaceutical Co., Ltd., for the development and commercialization of RBN-239

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today provided a business update and announced the appointment of a new Chief Financial Officer, Mr. Terig Hughes, in addition to the appointment of Dr. Gaetan Michel as Chief Operating Officer, Mr. Gael Forterre as Chief Commercial Officer, and Dr. Mark Eccleston as Chief Technology Officer

ZAGENO, a leading enterprise marketplace solution connecting eCommerce to life science, today announced Chris Wasley’s appointment as its Chief Financial Officer.